All About Asparaginase
Originally presented at HOPA's 14th Annual Conference, March 2018.
Asparaginase therapy is an integral component of achieving desirable outcomes in leukemia patients. Although asparaginase therapies have been a mainstay in pediatric acute lymphoblastic leukemia protocols for quite some time, as our understanding of their importance grows, these therapies are increasingly being used in adolescent and young adult protocols. Asparaginase therapy has many intricacies with regard to efficacy and safety. This presentation will review both the benefits of asparaginase therapies on treatment outcomes and their adverse-effect profile. The management of these adverse effects, including the differentiation of anaphylactic reactions versus infusion-related reactions, will be discussed in detail. We will also discuss the appropriateness of interchanging asparaginase products. Finally, we will focus on the utility and functionality of asparaginase monitoring through a review of recent literature on the pharmacokinetics and pharmacodynamics of the available formulations and optimization of monitoring to increase efficacy. This topic is especially timely because of the lack of national standardization in this area of practice and the recent publication of consensus recommendations for how asparaginase monitoring should be carried out.
Joshua Elder, PharmD BCOP BCPS
Patient Management & Therapeutics
The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. An ACPE statement of credit will be issued only upon completion of the pre/post- assessment and a post-activity evaluation form. ACPE credit must be claimed by March 22, 2021.
This activity has been approved for .1 CEU
This course is also included as part of the Best of 2018 Annual Conference Recordings Bundle.
Release Date: September 26, 2018
Expiration Date: March 22, 2021